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Abstract
Aberrant smooth muscle cell (SMC) plasticity has been implicated in a variety of vascular
disorders including atherosclerosis, restenosis, and abdominal aortic aneurysm (AAA) formation.
While the pathways governing this process remain unclear, epigenetic regulation by specific
microRNAs (miRNAs) has been demonstrated in SMCs. We hypothesized that additional
miRNAs might play an important role in determining vascular SMC phenotype. Microarray
analysis of miRNAs was performed on human aortic SMCs undergoing phenotypic switching in
response to serum withdrawal, and identified 31 significantly regulated entities. We chose the
highly conserved candidate miRNA-26a for additional studies. Inhibition of miRNA-26a
accelerated SMC differentiation, and also promoted apoptosis, while inhibiting proliferation and
migration. Overexpression of miRNA-26a blunted differentiation. As a potential mechanism, we
investigated whether miRNA-26a influences TGF-β-pathway signaling. Dual-luciferase reporter
assays demonstrated enhanced SMAD signaling with miRNA-26a inhibition, and the opposite
effect with miRNA-26a overexpression in transfected human cells. Furthermore, inhibition of
miRNA-26a increased gene expression of SMAD-1 and SMAD-4, while overexpression inhibited
SMAD-1. MicroRNA-26a was also found to be downregulated in two mouse models of AAA
formation (2.5- to 3.8-fold decrease, P < 0.02) in which enhanced switching from contractile to
synthetic phenotype occurs. In summary, miRNA-26a promotes vascular SMC proliferation while
inhibiting cellular differentiation and apoptosis, and alters TGF-β pathway signaling.
MicroRNA-26a represents an important new regulator of SMC biology and a potential therapeutic
target in AAA disease.
Smooth muscle cell (SMC) pathology is crucial to the progression of almost all vascular
disorders (Thompson et al., 1997; Doran et al., 2008; Inoue and Node, 2009). The vascular
SMC is unusual among muscle cells in its lack of terminal differentiation, possessing the
ability to assume a proliferative, migratory phenotype capable of synthesizing extracellular
matrix (ECM) (Owens, 1995). In conditions such as atherosclerosis or post-angioplasty
restenosis, SMC proliferation and increased cell cycling are viewed as deleterious and
maladaptive (Cai, 2006). In contrast, SMC re-growth is considered desirable during
aneurysmal dilation, which is typified by medial thinning (Hoshina et al., 2004).
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SMC phenotypic modulation occurs in response to a variety of stimuli, including growth
factors, reactive oxygen species, mechanical stress, and changes in extracellular structural
elements (Owens, 1995; McDonald and Owens, 2007). Despite considerable progress, no
definitive master regulators of SMC plasticity have yet been identified.
In the last decade, it has become clear that endogenous methods of post-transcriptional
genetic regulation exist, and that these mechanisms play a significant role in determining
cell fate and behavior (Fazi and Nervi, 2008). MicroRNAs (miRNAs) are single-stranded,
non-coding RNAs ~ 22 nucleotides in length, that typically function to induce degradation
or translational repression of specific target mRNAs (Li et al., 2008; Boettger et al., 2009).
Despite the existence of fewer than 1,000 known human miRNAs (Kong et al., 2009), it is
now apparent that more than 30% of the genome is regulated in this way (Gartel and Kandel,
2008). Functionally, miRNAs participate in every major cellular process, and have been
implicated in conditions such as cancer, heart disease, and developmental abnormalities
(Asli et al., 2008; Gartel and Kandel, 2008). In the vasculature, miRNAs regulate
angiogenesis, endothelial cell function, and vascular inflammation (Urbich et al., 2008).
However, little is known about the specific effects of miRNAs in SMCs. The majority of
studies to date have focused on a handful of largely pro-differentiation miRNAs and their
role in neointimal formation (Li et al., 2008; Boettger et al., 2009; Liu et al., 2009; Zhang,
2009).
To increase our understanding of vascular SMC pathobiology, we have performed the first
microarray study of miRNA expression in differentiating, growth-arrested human aortic
SMCs. As detailed below, we identified a group of miRNAs that are differentially regulated
during this process. A promising, largely un-studied candidate—miRNA-26a—was found to
inhibit SMC differentiation and apoptosis while promoting proliferation and migration,
possibly through a mechanism that targets TGF-β/BMP pathway signaling. MicroRNA-26a
was also significantly downregulated in developing murine abdominal aortic aneurysms
(AAAs) in vivo, and may represent a novel therapeutic target in conditions of pathological
aneurysmal dilation.
Materials and Methods
Cell culture
Human aortic SMCs (Lonza, Walkersville, MD, passage #3) were propagated in growth
media SmGM-2 (Lonza) in 5% fetal bovine serum (FBS) as per manufacturer’s instructions.
Control plates were harvested at 80% confluence. Serum-starved plates were incubated for
48 h (SS48) or 72 h (SS72) in serum-free basal media (SmBM) to induce growth arrest and
expression of SMC differentiation genes, according to conventional protocols (Owens et al.,
1986; Fager et al., 1989). Experimental plates were harvested for RNA or protein analysis at
~90% confluence. Samples included cells from two separate lots, as well as two technical
replicates per vial per time point.
Human embryonic kidney (HEK)-293 cells (ATCC, Manassas, VA) were propagated in
DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics
(Invitrogen, Carlsbad, CA) and used in transfection protocols described below.
MicroRNA and total RNA preparation, quantitative reverse-transcription PCR
Total RNA was isolated using the miRNeasy Mini Kit (Qiagen, Valencia, CA) as per
standard methods. RNA was quantitated by Nanodrop, and RNA and miRNA quality were
verified using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA—all
sample RNA integrity numbers > 9). For quantitation of gene transcription, cDNA was
generated with M-MuLV reverse transcriptase, and then amplified on the ABI PRISM
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7900HT with Taqman primers/probes (Applied Biosystems, Foster City, CA). Probes
included smooth muscle α-actin (ACTA2), smooth muscle myosin heavy chain (MYH11),
transgelin (TAGLN), SMAD family members 1 and 4 (SMAD1 and SMAD4), epidermal
growth factor receptor (EGFR), and high mobility group AT-hook 2 (HMGA2) all
normalized to 18S internal controls.
MicroRNAs were quantitated using Taqman miRNA Reverse Transcription Kits and
Taqman MicroRNA Assays (Applied Biosystems) or the GenoExplorer miRNA qRT-PCR
Kit (GenoSensor Corp., Tempe, AZ). Samples were normalized to endogenous controls
rnu48 or 5S RNA (human) and sno202 (mouse). All fold changes were calculated by the
method of ΔΔCt.
MicroRNA array hybridization and analysis
RNA samples were pooled by treatment group and hybridized to the Agilent Human miRNA
8×15k Array (v2) G4470B as per manufacturer’s protocol. This array contains probes for
723 human microRNAs from the Sanger database v.10.1. Arrays were scanned using an
Agilent Microarray Scanner and Feature Extractor (software v 9.5.1). Array results were
confirmed for miRNA-26a and miRNA-663 by qRT-PCR.
Array analysis
QC reports were generated by the Feature Extraction software, and the array data were
analyzed with Genespring GX 10.0.2 (Agilent). Arrays were examined with QC metrics,
principal components analysis (PCA), and hierarchical agglomerative clustering (HAC).
One chip (six arrays) clustered separately and was therefore excluded. Two additional arrays
were excluded for QC reasons. The remaining 10 arrays were subjected to one-way
ANOVA (cutoff of P < 0.05), with Benjamini–Hochberg correction for multiple testing.
Significant miRNAs were required to show >2.0-fold expression change from control at one
of the time points. Confirmatory pairwise analysis was performed between the control and
72 h time points using statistical analysis of microarrays (SAMs) with false detection ratio
(FDR) < 1 (Tusher et al., 2001). Targetscan 5.1 (Friedman et al., 2009) and Pictar (Krek et
al., 2005) were used to identify putative miRNA gene targets. Enrichment for KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathway categories and Gene Ontology (GO)
biological process categories were determined using DAVID (NCBI), with P < 0.05 cutoff.
All microarray data were submitted to the National Center for Biotechnology Information’s
Gene Expression Omnibus (GSE19544; http://www.ncbi.nlm.nih.gov/geo/).
Targeted miRNA inhibition and overexpression
MicroRNA-26a was inhibited with an antisense antagomiR (Applied Biosystems). SMCs
were transfected with high efficiency using the Amaxa Nucleofector system (Lonza)
employing protocol U-025. Successful transfection (>85% of all cells) was confirmed by
visual fluorescent microscopic analysis and fluorescence-activated cell sorting (FACS)
sorting for fluorescently labeled control anti-miR. The in vitro experiments detailed below
included an untransfected cohort of cells, and cohorts transfected with 100 nM of a probe
directed against miRNA-26a (AM10249) or a validated Cy3-labeled control probe known to
have no effect on any human miRNA (AM17011), as well as a cohort transfected with
miRNA-let7c as a positive control. Overexpression studies utilized 100nM of hsa-
miRNA-26a Pre-miR miRNA Precursor (Ambion—AM17100), in parallel with positive
(pre-miR hsa-miRNA-1) and negative controls from the Pre-miR miRNA Precursor Starter
Kit (Ambion—AM1540).
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Boyden chamber chemotaxis assays
To analyze SMC migration, a modified Boyden chamber assay was performed, as
previously described (Ishida et al., 2006). Briefly, 6-well trans-well migration chambers
with 8 µm pores (Becton Dickinson (BD), Franklin Lakes, NJ) were employed. AntagomiR-
transfected human aortic SMCs (5 × 104 cells/well) were serum starved in SmBM for 24 h
and then plated in the upper chamber in 1ml of SmBM. Two milliliters of SmGM-2 media
were added to the lower chamber, and the cells were allowed to migrate for 24 h at 37°C.
Cells that migrated to the lower chamber were fixed in methanol, stained with 0.1% crystal
violet and manually counted in a blinded fashion (eight high-power fields/well).
Proliferation and cell survival assays
A modified MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay
was performed to analyze SMC viability, as previously described (Erl et al., 2003).
AntagomiR-transfected SMCs were grown in 96-well plates for 24–36 h and then incubated
for 4 h in the presence of 10µl of MTT AB solution (Millipore, Billerica, MA). The
formazan product was dissolved by addition of 100 µl acidic isopropanol (0.04N HCl) and
absorbance was measured at 570 nm (reference wavelength 630 nm) on an ELISA plate
reader.
Apoptosis assays
Programmed cell death rates were assessed with a commercially available apoptosis assay
(BD). AntagomiR-transfected human aortic SMCs were treated with 10% H2O2 in serum
free media for 6 h. Then, 1 × 105 cells were harvested and stained with 10 µl FITC Annexin
V and 10µl propidium iodide and FACS sorted within 1 h (BD FACSCaliber, 530 nm [FL1]
and >575 nm [FL3]).
Western blots
Transfected human aortic SMCs were serum starved in SmBM for 48 h and then treated
with transforming growth factor-β (5 ng/ml, hTGF-β1, R&D Systems, Minneapolis, MN)
for an additional 24 h. Total cellular protein was isolated and analyzed as previously
described (Yue et al., 2010). Cell lysates were subjected to Western blotting with primary
antibodies directed against human SMAD-1 (1:500), and SMAD-4 (1:1,000) (Abcam,
Cambridge, MA) and an HRP-conjugated goat–anti-rabbit secondary antibody (1:2,000)
(Cell Signaling, Danvers, MA). Exposed films were scanned, and integrated band densities
were obtained after background subtraction using ImageJ software in a blinded fashion.
SMAD reporter assays
TGF-β-induced signal transduction was probed using a SMAD reporter construct Cignal
Reporter Assay Kit (SABiosciences, Frederick, MD—CCS-017L), which encodes the firefly
luciferase reporter gene under the control of a minimal (m)CMV promoter and tandem
repeats of the SMAD transcriptional response element (TRE). Firefly reporters came
premixed with separate plasmids constitutively expressing Renilla luciferase. Negative and
positive reporter controls and SMAD reporter with and without pre-miR precursors (pre-
miRNA-26a or negative control), and antagomiRs (anti-miRNA-26a or negative control)
were transfected in triplicate into both human aortic SMCs and HEK-293 cells with
Lipofectamine 2000 as per manufacturer’s protocol (Invitrogen 11668-019). After 6 h of
transfection, the media were changed to Opti-MEM I + 1% NEAA (Invitrogen), with or
without hTGF-β1 at 2.5 ng/ml. Cells were then harvested after 18 h and analyzed by Dual-
Luciferase Reporter Assay (Promega, Madison, WI) per kit protocol. Results were
normalized to basal activity of untreated SMAD reporter.
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Murine AAA models
All protocols were approved by the Administrative Panel on Laboratory Animal Care at
Stanford University (http://labanimals.stanford.edu/). Both the porcine pancreatic elastase
(PPE) and the ApoE−/−/Angiotensin II (AngII) models were employed in this study to
evaluate two relevant models of AAA disease.
First, male ApoE−/− mice (C57BL/6J background) (n = 4/group), aged 10 weeks old (25–30
g, Jackson Laboratories, Bar Harbor, ME) underwent AAA creation via elastase infusion, as
previously described (Azuma et al., 2009). Briefly, the infra-renal abdominal aortas were
isolated and temporary ligatures were applied. Saline solution containing 4.5U/ml type 1
PPE (E-1250; Sigma, St. Louis, MO) was instilled for 5 min at 100 mmHg. The aortotomy
was closed with 10–0 suture, and aortic flow restored. Mice were euthanized at time 0, 3
days, and 7 days, and harvested aortas were immediately flash-frozen in liquid nitrogen.
Standard immunohistochemistry analysis employing a monoclonal SMC α-actin antibody
(Clone A14; Sigma) was performed (Chun et al., 2008).
A second cohort of male ApoE−/− (C57BL/6J background) mice were exposed to
continuous AngII infusions (1.4 mg/kg/day, Sigma) via subcutaneous osmotic minipumps
(model 2004, Alzet, Cupertino, CA) (Chun et al., 2008). In a separate study, whole genome
transcriptional profiling of supra-renal abdominal aortic tissue was performed to identify
expression changes versus saline control at the 1-week time point (Spin et al., 2009). Genes
upregulated with AngII at day 7 were cross-referenced against the putative target list for
miRNA-26a. Using DAVID, we identified overlapping GO biological process categories
within the common gene lists.
Statistical analysis
Data are presented as mean ± SEM. All in vitro experiments included at least four replicates
per group. Data were subjected to the Kolmogorov–Smirnov test to determine distribution.
Groups were compared using the two-tailed Student’s t-test for parametric data. A value of
P < 0.05 was considered statistically significant. Data analysis was performed on GraphPad
Prism 3.02 software.
Results
SMC differentiation, gene expression, and miRNA modulation with serum starvation
As expected, serum-starved human aortic smooth muscle cells (AoSMC) showed significant
and generally progressive increases in the expression of differentiation marker genes by
qRT-PCR at 48 and 72 h, including smooth muscle myosin heavy chain (9.2- and 37.8-fold),
SM α-actin (15.6- and 20.8-fold), and SM22α/transgelin (2.3- and 2.0-fold) (P < 0.001 for
all comparisons vs. control).
MicroRNA array analysis comparing control (serum-fed) and serum-starved samples (SS48
and SS72) yielded 135 significantly regulated miRNAs. Thirty-one of these miRNAs had
fold changes >2.0 (28 upregulated and 3 downregulated), and each of these was also
significant at FDR < 1 by SAM (Fig. 1A and Supplementary Table 1A). Most changes
occurred in a progressive fashion over time (71% showed higher fold changes vs. control at
72 h than at 48 h).
Treatment groups showed clear separation with PCA and HAC clustering algorithms
(Supplementary Fig. 1A). A few miRNA known to be associated with vascular gene
regulation and with SMCs in particular were differentially regulated by both methods used,
but only passed a 1.5-fold change cutoff, including miRNA-21 (1.6-fold increased at 72 h),
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and miRNA-221 (1.5-fold decreased at 72 h). Another established SMC differentiation-
related miRNA, miRNA-145, was up 3.6-fold at 72 h, and was the highest-ranked miRNA
by SAM.
Targetscan and Pictar were used to identify putative conserved gene targets of the
differentially upregulated miRNAs. Resultant gene lists were probed for significantly
overabundant canonical pathways (KEGG) and GO biological process groups using DAVID
(Fig. 1B) (Huang da et al., 2007, 2009). Apart from miRNA-145, miRNA-26a was the
highest-ranked (by SAM) feature for both time-point comparisons that was enriched for
putative targets likely related to SMC biology, atherosclerosis, and aortic aneurysm
formation, including genes from the cell cycling, TGF-β, cell adhesion, p53, and Wnt
pathways among others (Fig. 1C). In particular, miRNA-26a is believed to regulate
SMAD-1 (Luzi et al., 2008), and also has SMAD-4 as a putative target. We confirmed the
expression levels for miRNA-26a (1.54-fold increase vs. serum fed [range 1.2–2.1]) with 72
h of serum starvation by Taqman/qRT-PCR in aortic SMC from three separate individuals.
MicroRNA-26a regulates several aspects of SMC biology including proliferation,
differentiation, migration, and apoptosis
Because miRNA-26a was significantly upregulated during SMC differentiation and was
predicted to regulate critical cell-fate pathways, we next investigated the physiological
properties of this miRNA in a series of loss-of-function experiments. Interestingly, human
aortic SMCs deficient in miRNA-26a actually demonstrated a modest acceleration in
appearance of differentiation markers relative to control cells (Fig. 2). Cells transfected with
the anti-miRNA-26a antagomiR revealed a more pronounced rise in both smooth muscle
myosin heavy chain (MYH11) expression (25.7 ± 8.2 vs. 9.4 ± 2.7-fold increase, P < 0.05)
and smooth muscle α-actin (ACTA2) (3.3 ± 0.6 vs. 2.7 ± 0.9-fold increase) after 72 h of
serum starvation, compared to cells transfected with a control antagomiR. Further, aortic
SMCs transfected with miRNA-26a pre-miR precursor and serum starved for 72 h displayed
significant blunting of the usual increase in differentiation marker expression when
compared with transfected negative control pre-miR (MYH11: 4.2 ± 0.4 vs. 16.8 ± 2.6-fold
increase, P < 0.001; ACTA2: 9.2 ± 0.7 vs. 16.0 ± 0.5-fold increase, P < 0.05).
In keeping with this anti-differentiation effect, aortic SMCs deficient in miRNA-26a also
revealed significant reductions in proliferation (0.037 ± 0.002 vs. 0.050 ± 0.002 relative
proliferation units, P < 0.001) and migration (18.9 ± 1.8 vs. 67.6 ± 5.5 cells/hpf, P < 0.001),
and a significant increase in the rate of H2O2-induced apoptosis (4.5 ± 0.3% vs. 3.2 ± 0.1%,
P < 0.01), relative to control transfected cells (Fig. 3A–C).
MicroRNA-26a regulates the TGF-β signaling cascade
In order to elucidate the mechanism by which miRNA-26a modulates SMC processes, we
assessed the effect of miRNA-26a on the pro-differentiation TGF-β cascade (Fig. 4). Cells
were co-transfected with a SMAD firefly luciferase reporter, a constitutively expressing
Renilla luciferase reporter, and either miRNA-26a antagomiR or pre-miR precursor. Success
of the transfection protocol was confirmed using green fluorescent protein-expressing
positive controls.
As expected, basal TGF-β pathway activity in growing AoSMC and HEK-293 cells was
quite low, and comparable to negative control reporter. Addition of hTGF-β1 at 2.5 ng/ml to
HEK-293 cells led to a substantial (~37-fold) increase in SMAD reporter activation.
AntagomiR inhibition of miRNA-26a combined with TGF-β in HEK-293 cells caused a
significant increase in SMAD activity beyond that seen with TGF-β alone (1.36-fold, P <
0.05), while pre-miR-induced overexpression of miRNA-26a significantly decreased SMAD
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activity levels (−1.74-fold, P < 0.05). MicroRNA-26a antagomiR and pre-miR precursor
transfection had no impact on basal SMAD activity in the absence of TGF-β, implying that
this mechanism requires pathway activation by TGF-β in order to exert an effect. Negative
control pre- and antagomiRs did not significantly alter reporter activity (Supplementary Fig.
2). Despite lower SMAD-reporter luciferase signal levels in AoSMCs, the reporter activity
was similar to the pattern observed for HEK-293 cells (data not shown).
MicroRNA-26a targets the expression of SMAD-1 and SMAD-4, members of the TGF-β
superfamily signaling cascade
Because miRNA-26a has been predicted to target SMAD-1 and SMAD-4, we next assessed
the direct effects of miRNA-26a on the expression of these pro-differentiation TGF-β/BMP
cascade molecules (Fig. 5A). Compared to negative control transfected cells, SMC
transfected with anti-miRNA-26a antagomiR displayed increases in the expression of both
SMAD1 (2.3- to 3.5-fold-change range, P < 0.05) and SMAD4 (1.6- to 3.3-fold-change
range, P < 0.05) after 72 h of serum starvation. Negative control antagomiR caused no
change in SMAD-1/4 expression, while transfection with anti-miRNA-let7c as a positive
control caused a 2.0- to 5.1-fold-change range increase of HMGA2 (P < 0.05).
In keeping with the results of these knockdown experiments, overexpression of miR-26a
decreased SMAD-1 expression compared with negative control pre-miR precursor
transfected cells an average of 1.5-fold (P < 0.05), although SMAD-4 expression did not
change significantly. No change was seen between negative control pre-miR precursor and
mock-transfected cells for SMAD-1/4. For comparison, transfected positive control pre-
miR-1 decreased its known target EGFR 1.7-fold versus negative control pre-miR precursor
(P < 0.05).
To confirm this effect at the protein level, transfected AoSMCs were subsequently treated
with TGF-β and then harvested for Western blot analysis. One day after treatment, cells
deficient in miRNA-26a displayed a qualitative increase in the rate of SMAD-1 and
SMAD-4 expression after TGF-β exposure (Fig. 5B). Densitometric analysis of these blots
confirmed a 1.59-fold greater expression of SMAD-1 protein and a 1.16-fold greater
expression of SMAD-4 protein in cells treated with 5 ng/ml of TGF-β.
MicroRNA-26a is downregulated during AAA formation
We next evaluated the expression of miRNA-26a in two murine AAA development models
to extend our in vitro findings in vivo. Compared to baseline, miRNA-26a expression in the
aneurysm wall was reduced significantly 3 days after infusion in the elastase model (2.3-fold
by qRT-PCR, P < 0.001), and this reduction was accentuated further at 7 days (3.8-fold, P <
0.02) (Fig. 6A). Similar results were observed in the AngII–ApoE−/− AAA model, where
miRNA-26a was also significantly downregulated within the suprarenal aortic wall 1 week
after beginning AngII infusion (vs. saline infusion, 2.5-fold, P < 0.001, Fig. 6B).
Histopathological analysis revealed that the observed decrease in miRNA-26a expression
coincided temporally with decreased SM α-actin staining, and vessel dilation (Fig. 6C) (Van
Vickle-Chavez et al., 2006). In addition, the expression of potentially related microRNA
miRNA-21 was increased in the elastase model of AAA (2.5-fold increase at day 3, P <
0.001; 3.9-fold increase at day 7).
The list of conserved putative miRNA-26a target genes was cross-referenced against a list of
aortic genes, we found to be upregulated in the AngII–ApoE−/− model AAA wall at 7 days,
in which classic as well as novel genes were identified (e.g., Spp1, Ctgf, Mmp2, Mmp3, and
thousands more—full article under review) (Spin et al., 2009). Of 535 predicted conserved
miRNA-26a target genes, 124 were increased during AAA formation (including such genes
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as Smad1 and Smad4, Loxl2, and Inhbb). As shown in Figure 6D, many of these genes were
members of the cell cycling, apoptosis, proliferation/migration, cytokine production, and
TGF-β receptor pathway signaling GO categories, linking miRNA-26a more closely to
disease-relevant vascular SMC processes.
Discussion
Smooth muscle cell plasticity is a critical determinant of vessel wall disease. The ability of
these cells to modulate their phenotype from a quiescent, contractile state to a proliferative,
synthetic profile has been implicated in conditions such as atherosclerosis, post-angioplasty
restenosis, and aortic aneurysm formation (Thompson et al., 1997; Hoshina et al., 2004; Cai,
2006; Doran et al., 2008; Inoue and Node, 2009). While some of the basic aspects
underlying regulation of SMC phenotypic change have been elucidated, the ways in which
miRNAs might initiate or modify the process are not well understood.
We sought to clarify this question by performing the first in vitro miRNA microarray
analysis of human vascular smooth muscle cells induced to differentiate via serum
starvation/growth arrest. Employing an agnostic whole-genome approach, we identified 28-
upregulated and 3-downregulated miRNAs that were significantly and sustainably altered
during the differentiation process.
As expected, several miRNAs known to be involved in vascular physiology were found to
be differentially regulated with serum starvation, including miRNA-145, miRNA-21, and
miRNA-221 (although of these only miRNA-145 showed > 2.0-fold change vs. control).
However, the majority of the significantly regulated miRNAs, we identified have never
previously been implicated in SMC biology. Bioinformatic analysis revealed that the
putative targets of the upregulated miRNAs were enriched for several ontologic pathways
relevant to SMC phenotypic change and disease, including cytoskeletal regulation, Wnt and
TGF-β pathways, p53 signaling, and cell–matrix interactions (Fig. 1).
Among the highest-ranked significant genes was miRNA-26a. Ontologic analysis singled
out this miRNA as a particularly interesting candidate. Given its highly conserved status (in
contrast to the most highly regulated gene, miRNA-663, which does not exist in the mouse
or rat) and large number of predicted targets within SMC-related pathways (Fig. 1), we
surmised that miRNA-26a could be a key regulator of SMC physiology.
Despite being significantly upregulated during SMC differentiation, we found that
knockdown of miRNA-26a actually accelerated the appearance of SMC differentiation
marker genes with serum starvation, while overexpression of miRNA-26a blunted marker
appearance. We postulate that the differentiation-associated upregulation of miRNA-26a
might be a compensatory negative-feedback mechanism, and that miRNA-26a actually
serves as an inhibitor of SMC differentiation. In keeping with this hypothesis, we found that
cells deficient in miRNA-26a displayed significantly decreased rates of cell cycling, and
were less able to effectively migrate toward a growth factor/serum gradient relative to
control cells. Furthermore, cells deficient in miRNA-26a displayed significantly enhanced
rates of programmed cell death.
Given its predicted gene targets, miRNA-26a may alter vascular SMC biology in part via an
inhibitory effect on the signaling pathways downstream of the TGF-β/BMP superfamily of
growth factors. Although complementary base pair modeling with thermodynamic stability
calculations predicts hundreds of potential targets for miRNA-26a-induced translational
repression, two of the most strongly predicted targets for degradation include the TGF-β and
bone morphogenetic pathway (BMP)-related pro-differentiation factors, SMAD-1 and
SMAD-4. Prior evidence suggested that miRNA-26a inhibits SMAD-1 (Luzi et al., 2008).
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We confirmed this interaction in SMCs, observing that cells deficient in miRNA-26a
expressed more SMAD-1 and SMAD-4 than cells with intact miRNA-26a both at the RNA
and protein level. Similarly, overexpression of miRNA-26a suppressed the expression of
SMAD-1, although not SMAD-4. Solidifying this link, we found that miRNA-26a inhibited
the activity of a SMAD2/3/4-reporter, confirming that miRNA-26a directly modulates the
TGF-β signaling cascade.
These effects on the TGF-β pathway, and on SMC proliferation, migration, and apoptosis in
particular, suggested that miRNA-26a could be important in AAA development. SMCs
display profound de-differentiation early in the formation of experimental animal AAAs
(Ailawadi et al., 2009). Some SMC apoptosis also occurs in both human AAA and murine
AAA models (Thompson et al., 1997; Henderson et al., 1999; Sho et al., 2005). It was
therefore interesting to find that miRNA-26a is significantly and progressively
downregulated in two independent mouse models of AAA disease, and that loss of
miRNA-26a expression coincides temporally with loss of medial SM α-actin staining and
radial aortic dilation, consistent with our in vitro results. It should be noted that other cell
types within the aortic wall may have contributed to the observed gene signal, and that some
SMC cell loss does occur during AAA formation. However, medial SMC still represent the
majority of the cells in the post-treatment aortic wall. MicroRNA-26a has several putative
gene targets tied to apoptosis. Notably three of these, BAK1 (BCL2-antagonist/killer 1),
PAK2 (p21 protein (Cdc42/Rac)-activated kinase 2), and SULF1 (sulfatase 1) are pro-
apoptotic genes also found to be upregulated in the wall of developing AngII–ApoE−/−I
murine aortic aneurysms (Spin et al., 2009). More detailed studies of miRNA-26a function
in AAA models are needed to clarify its role.
It appears, therefore, that miRNA-26a may function as a ‘biological brake’ that dampens
cellular differentiation in culture. By inhibiting critical SMAD signaling proteins
downstream of TGF-β/BMP-family receptors, as well as other possible pathway-related
targets, miRNA-26a helps maintain the balance of cells in the synthetic and contractile states
and governs phenotypic shifting (Fig. 7). A caveat to this hypothesis is that SMAD-1 is
primarily an element of BMP-responsive pathways, while SMAD-4 is in the common
pathway for BMP and TGF-β. Future experiments will specifically evaluate the effects of
miRNA-26a on BMP-triggered signaling. Also, SMAD protein activity is thought to be
primarily dependent on posttranslational phosphorylation, suggesting that non-SMAD
targets of miRNA-26a may also play a significant role in its modulation of SMC phenotype.
Previously, miRNA-26a had been reported to induce conflicting effects on cellular fate and
survival in cell types of differing origins (Luzi et al., 2008; Wong and Tellam, 2008;
Ciarapica et al., 2009; Huse et al., 2009; Kota et al., 2009; Sander et al., 2009). In contrast to
the findings reported here, miRNA-26a has been implicated as a potent inducer of skeletal
myogenesis (Wong and Tellam, 2008; Ciarapica et al., 2009) and a promoter of cell cycling
arrest in proliferating hepatocellular carcinoma and lymphomatous cells (Kota et al., 2009;
Sander et al., 2009). Conversely, other studies have shown that miRNA-26a can inhibit
differentiation as adipose-derived stem cells evolve towards lineage-committed osteoblasts,
and in malignant glioblastoma tissue (Luzi et al., 2008; Huse et al., 2009). Such remarkable
cell-specific biological heterogeneity has been described previously for other microRNAs (Ji
et al., 2007). In the case of miRNA-26a, these observed differences are likely due to varying
ratios of antagonistic molecular targets in tissue from differing lineages (Huse et al., 2009).
In fact, it is conceivable that the seemingly opposite effects of TGF-β on endothelial and
smooth muscle constituents of the vessel wall may be due, in part, to the unique properties
of miRNA-26a in different cell types (Pollman et al., 1999).
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In conclusion, this microarray-based study found numerous significantly regulated miRNAs
with SMC differentiation in culture. In particular, we identified miRNA-26a as a potentially
critical regulator of SMC biology, a promoter of cell cycling and migration, and an inhibitor
of apoptosis. MicroRNA-26a joins miRNA-21a and miRNA-221 as the only microRNAs
known to inhibit SMC differentiation (Ji et al., 2007; Davis et al., 2009; Liu et al., 2009).
We hypothesize that miRNA-26a may serve an evolutionary role in the repair of damaged
blood vessels, inducing SMC proliferation and medial repopulation in response to
pathological conditions such as aneurysm dilation. Future studies should evaluate the effect
of miRNA-26a replacement or inhibition on the progression ofAAAdisease—a leading
cause of morbidity and mortality.
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Fig. 1.
MicroRNAs are differentially regulated during SMC differentiation and are predicted to
target genes relevant to vascular biology. A: After 48 h (SS48) and 72 h (SS72) of serum
starvation, 31 miRNAs were significantly modulated. The expression change (log 2) for
each regulated miRNA is detailed in part A, ordered by fold change. See text for statistics.
MicroRNA-26a is highlighted. B: Analysis of the conserved putative target lists for all 28
upregulated miRNAs (using Targetscan, Pictar, and DAVID) revealed several significantly
enriched KEGG pathways (P < 0.05). Number of target genes/category shown. C: Analysis
of the conserved putative targets of miRNA-26a reveals several enriched KEGG pathways
(P < 0.05). Number of target genes/category shown.
Leeper et al. Page 13
J Cell Physiol. Author manuscript; available in PMC 2011 June 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
MicroRNA-26a regulates the rise of SMC markers during serum starvation induced
differentiation over 72 h. Left: Smooth muscle α-actin (ACTA2) expression is enhanced by
anti-miRNA-26a, and blunted by miRNA-26a pre-miR precursor when compared to
negative control antagomiR and pre-miR. Right: Similar findings are seen for smooth
muscle myosin heavy chain (MYH11) expression. *P < 0.05.
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Fig. 3.
MicroRNA-26a regulates multiple aspects of SMC phenotype. Relative to control-
transfected cells, human aortic SMC deficient in miRNA-26a display. A: Reduced rates of
cellular proliferation. B: Reduced rates of cellular migration (representative Boyden
chambers shown top right, 6 × magnification). C: Enhanced rates of apoptosis.
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Fig. 4.
MicroRNA-26a controls the activity of a TGF-β-activated SMAD reporter element.
HEK-293 cells were dual-transfected with firefly luciferase SMAD reporter/constitutively
expressing Renilla luciferase and either miRNA-26a antagomiR or pre-miR precursor, and
treated with TGF-β. As expected, TGF-β treatment increased transcription of the SMAD-
responsive TREs (SMAD/TGFβ), *P < 0.05 versus untreated reporter (SMAD). Addition of
pre-miRNA-26a (SMAD/TGFβ/pre-26a) caused a significant drop in signaling compared
with TGF-β-treated cells, while miRNA-26a antagomiR (SMAD/TGFβ/anti-26a) led to a
significant activity increase, **P < 0.05.
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Fig. 5.
A: SMAD-1 and SMAD-4 are putative targets of miRNA-26a. Human aortic SMCs
deficient in miRNA-26a display enhanced expression ofSMAD-1 and SMAD-4, while
overexpression of miRNA-26a lowers expression ofSMAD-1 (*P < 0.05). Error bars
indicate fold-change range derived per protocol (Applied Biosystems). B: Representative
Western blots confirm increased SMAD-1/4 levels with inhibition of miRNA-26a in cells
treated with 5 ng/ml of TGF-β. Left lanes: negative control antagomiR. Right lanes: anti-
miRNA-26a.
Leeper et al. Page 17
J Cell Physiol. Author manuscript; available in PMC 2011 June 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 6.
MicroRNA-26a is downregulated during AAA formation. A, B: Compared to baseline,
miRNA-26a expression is significantly decreased in both the murineelastase aneurysm
model (A) and the ApoE−/−/Ang II aneurysm model (B) during lesion progression. C: Loss
of miRNA-26a occurs at a time point when SMC de-differentiation is pronounced.
Representative micrographs of non-dilated vessels (top) and day 7 elastase-treated
aneurysmal aortas (bottom) reveal arelative deficiency of SM-α actin-expressing medial
SMCs as AAAs develop (20 × magnification, IHC for SM-α actin in red). Note the
preserved staining in the unaffected vasavasorum of the aneurysmal vessel. D: Predicted
miRNA-26a targets are differentially regulated during AAA progression. The Venn diagram
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demonstrates overlap of Gene Ontology categories between miRNA-26a target genes and
genes significantly upregulated during AAA development in the ApoE−/−/AngII model,
minimum 2 genes/category.
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Fig. 7.
Putative mechanism by which miRNA-26a may target TGF-β/BMP signaling to alter SMC
biology.
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